Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy
暂无分享,去创建一个
R. Tibshirani | I. Lossos | Y. Natkunam | C. Hans | M. Bast | Shuchun Zhao | A. Nagler | E. Hsi | B. Pohlman | D. Gratzinger | A. Avigdor | G. Schiby | G. Byrne
[1] J. Dorsman,et al. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. , 2007, Biochemical pharmacology.
[2] Amy V Kapp,et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. , 2007, The American journal of pathology.
[3] K. Podar,et al. Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies , 2007, Cell cycle.
[4] J. Verweij,et al. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.
[5] A. Giatromanolaki,et al. Angiogenesis in Colorectal Cancer: Prognostic and Therapeutic Implications , 2006, American journal of clinical oncology.
[6] S. Fox,et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Claesson‐Welsh,et al. VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.
[8] I. Lossos,et al. Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Gordon,et al. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis , 2006, Leukemia & lymphoma.
[10] J. Raemaekers,et al. Angiogenesis in malignant lymphoma , 2005, Current opinion in oncology.
[11] H. Johnsen,et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma , 2005, Annals of Hematology.
[12] K. Podar,et al. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.
[13] Yasodha Natkunam,et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.
[14] J. Raemaekers,et al. Increased vascularization predicts favorable outcome in follicular lymphoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] J. Teruya-Feldstein,et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. , 2004, Blood.
[16] K. Kihara,et al. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids , 2004, Molecular and Cellular Endocrinology.
[17] Santhosh K. P. Kumar,et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy , 2004, Bone Marrow Transplantation.
[18] H. Joensuu,et al. Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma , 2003, Cancer.
[19] K. Norrby,et al. Tumour‐type‐specific capillary endothelial cell stainability in malignant B‐cell lymphomas using antibodies against CD31, CD34 and Factor VIII , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[20] N. Ferrara,et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.
[21] Lena Claesson-Welsh,et al. VEGF Receptor Signal Transduction , 2001, Science's STKE.
[22] I. Avramis,et al. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. , 2001, Anticancer research.
[23] H. Joensuu,et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.
[24] O. Bairey,et al. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas , 2000, Medical oncology.
[25] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Machein,et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells , 1999, Neuropathology and applied neurobiology.
[27] T. Noda,et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Volm,et al. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. , 1997, Anticancer research.
[29] R. Kurzrock,et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Ribatti,et al. Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.
[31] J. Blay,et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.
[32] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.